Optimizing the Radiotherapy plan according to tumor shrinkage in Head and Neck Cancers-A Prilimenary Study
Not Applicable
- Conditions
- Health Condition 1: null- Head and Neck Cancer patients who will be suitable for Radical Chemo-radiotherapy will be recruited for this study
- Registration Number
- CTRI/2018/01/011637
- Lead Sponsor
- CSIR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age > 18 years
Histologically proven squamous cell carcinoma
Written informed consent
Locally advanced head and neck cancers
Exclusion Criteria
1.Resection of primary tumor
2.Delivery of induction chemotherapy prio to radiation
3.Prior history of malignancy
4.History of prior radiation
5.KPS <70
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie tumor shrinkage in head and neck cancers during adaptive radiotherapy?
How does adaptive radiotherapy compare to conventional chemo-radiotherapy in treating head and neck cancers?
Which biomarkers are most predictive of response to adaptive radiotherapy in head and neck cancer patients?
What are the common adverse events associated with adaptive radiotherapy for head and neck cancers and their management?
Are there any combination therapies or targeted agents being explored alongside adaptive radiotherapy for head and neck cancers?